Business Wire (press release) RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to ...
Proactive Investors UK Salix Pharmaceuticals – Co. has announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam, for the treatment of ulcerative proctitis. In each of the two pivotal Phase 3 studies ... and more »
StreetInsider.com (subscription) Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis (UP) or ... and more »
Insider Monkey (blog) The first significant development to digest is that Santarus recently received a favorable ruling by an appellate court on a patent lawsuit that blocked the use of a generic form of their drug, Zegerid (also known as Omeprazole /sodium bicarbonate ...
4-traders (press release) Budesonide foam, RELISTOR® , LUMACAN? and rifaximin for additional indications are under development. For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN and ... and more »
7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
Seeking Alpha We get about 10% absorption of the budesonide . We've estimated peak sales of $300 million for this product. And you'll see some data later that gives you some relativity of why we think we can do at least $300 million in sales. We launched the product ... and more »
EON: Enhanced Online News (press release) UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID ( omeprazole /sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are ...
